• Medientyp: E-Book; Hochschulschrift
  • Titel: Untersuchungen zur prognostischen Relevanz des L-Carnitin-Transporters OCTN2 im Glioblastoma multiforme mit in vitro-Charakterisierung seines zytoprotektiv wirksamen Substrats L-Carnitin in humanen Glioblastomzellen
  • Beteiligte: Fink, Matthias A. [VerfasserIn]; Schroeder, Henry [AkademischeR BetreuerIn]; Rohde, Veit [AkademischeR BetreuerIn]; Bien-Möller, Sandra [AkademischeR BetreuerIn]
  • Körperschaft: Universität Greifswald
  • Erschienen: Greifswald, 2016
  • Umfang: 1 Online-Ressource (PDF-Datei: 160 Seiten, 11935 Kilobyte); Illustrationen (teilweise farbig), Diagramme (teilweise farbig)
  • Sprache: Deutsch
  • Identifikator:
  • Schlagwörter: Glioblastom > Zelle > Levocarnitin > Carnitin
  • Entstehung:
  • Hochschulschrift: Dissertation, Universitätsmedizin der Universität Greifswald, 2019
  • Anmerkungen: Literaturverzeichnis: Seite 121-145
  • Beschreibung: Glioblastoma multiforme, L-Carnitin, OCTN2

    Glioblastoma (GBM) is highly resistant to treatment, largely due to disease heterogeneity and resistance mechanisms. Understanding the mechanisms that generate resistance is essential for developing more effective treatment strategies. Recent studies provide evidence that OCTN2 and its substrate L-carnitine (LC) function as a cytoprotective system that strengthens cellular robustness. Here, we report on the expression and prognostic impact of the OCTN2/LC system in resected specimens of patients with newly diagnosed and recurrent GBM compared with healthy brain. We identified a high OCTN2 expression profile to correlate with a poor prognosis in patients with primary GBM, especially in those with a holistic therapeutical approach (total tumor resection, radiochemotherapy according to the Stupp protocol). The mechanistic studies indicate that inhibition of the OCTN2/LC system could reduce survival of GBM cells through enhanced sensitivity to exogenous influences such as hypoxic, metabolic, and cytotoxic stress. In summary, our study stresses the role of OCTN2/LC as an actor in GBM cytoprotection, representing a potential target for clinical therapies aimed to slow the growth and progression of GBM.
  • Zugangsstatus: Freier Zugang